CRISPR/Cas9 was implemented to KO the common CRC mutant genes (APC, TP53, KRAS, SMSD4) in intestinal organoid stem cell lines that were independent of all stem cell growth factors in vitro to create a cell line model closer to the natural tumor environment and independent of growth factors. Here, KRAS is linked to neoplasm.